COM-701
- Generic Name
- COM-701
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Phase 1
Recruiting
- Conditions
- Ovarian CancerOvarian Cancer Recurrent
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06888921
- Locations
- 🇺🇸
West Cancer Center, Germantown, Tennessee, United States
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Phase 1
Completed
- Conditions
- Advanced CancerOvarian CancerBreast CancerLung CancerEndometrial CancerOvarian NeoplasmTriple Negative Breast CancerLung NeoplasmNeoplasm MalignantColo-rectal Cancer
- Interventions
- Drug: COM701 with Opdivo (Nivolumab).
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 121
- Registration Number
- NCT03667716
- Locations
- 🇺🇸
University of California Los Angeles (UCLA)., Los Angeles, California, United States
🇺🇸M D Anderson Cancer Center., Houston, Texas, United States
🇺🇸The START Center for Cancer Care., San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath